These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24052561)

  • 1. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
    Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
    Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
    Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
    Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
    J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
    Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.
    Kirby RJ; Qi F; Phatak S; Smith LH; Malany S
    Toxicol Appl Pharmacol; 2016 Aug; 305():250-258. PubMed ID: 27343406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.
    Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ
    Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.